维持治疗中加用糖皮质激素不降低ANCA相关血管炎重大复发风险:纵向队列真实世界数据
该回顾性队列研究纳入171例新诊断GPA或MPA患者,中位随访88.2个月,评估维持治疗期低剂量糖皮质激素对重大复发、住院和损伤累积的影响。多因素分析显示低剂量GC未降低重大复发风险(HR=0.96,95%CI 0.88-1.05,p=0.36),但与损伤累积(HR=1.52,95%CI 1.19-1.93,p=0.0007)和住院(HR=1.24,95%CI 1.06-1.45,p=0.006)风险升高相关。
要点
- 维持期低剂量GC未显著降低GPA/MPA重大复发风险。
- 维持期GC暴露与损伤累积和住院风险升高相关。
- 利妥昔单抗使用与重大复发风险降低相关。
核心结论
- 维持治疗期较高的GC暴露未显著降低重大复发风险,而与损伤累积和住院相关。
研究设计与样本
- 回顾性队列研究,纳入三个三级转诊中心新诊断的GPA或MPA患者171例(GPA 107例,MPA 64例,中位年龄61岁),中位随访88.2个月(803.4患者年)。
主要发现
- 共记录65次重大复发(8.1/100患者年)发生于48例患者(28%),65次新发损伤事件(8.1/100患者年)和132次住院(16.4/100患者年)。
- 多因素分析中,利妥昔单抗使用与重大复发风险降低相关(HR=0.21,95%CI 0.09-0.47,p=0.0001),诊断时疾病活动度与重大复发风险升高相关(HR=1.17,95%CI 1.03-1.33,p=0.013)。
- 低剂量GC与重大复发风险降低无关(HR=0.96,95%CI 0.88-1.05,p=0.36),但与损伤累积风险(HR=1.52,95%CI 1.19-1.93,p=0.0007)和住院风险(HR=1.24,95%CI 1.06-1.45,p=0.006)相关。
临床怎么用
- 在GPA/MPA维持治疗决策中,应权衡长期GC使用对复发预防的有限获益与其与损伤累积和住院风险的关联。
局限性
- 回顾性队列设计,虽进行敏感性分析处理潜在混杂,但原文未报告具体敏感性分析结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the role of low-dose glucocorticoids (GCs) in major relapse, hospitalisation and damage accumulation risk during maintenance therapy in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAVs). METHODS: Retrospective cohort study of newly diagnosed patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) followed in three tertiary referral centres. We recorded relapses (Birmingham Vasculitis Activity Score increase >0), increases in Vasculitis Damage Index (VDI) and hospitalisations. We used time-varying and mixed-effects Cox models to examine the effect of GCs on the risk of major relapses, VDI accumulation and hospitalisations. Sensitivity analysis was also conducted to address potential confounding. RESULTS: 171 patients (GPA: 107, MPA: 64, median age: 61 years) were included with a median follow-up of 88.2 months (803.4 patient years (PY)). We recorded 65 major relapses (8.1/100 PY) in 48 patients (28%), 65 events of new damage (8.1/100 PY) and 132 hospitalisations (16.4/100 PY). By multivariable analysis, rituximab use was associated with a lower risk (HR=0.21, 95% CI 0.09 to 0.47, p=0.0001) while disease activity at diagnosis was associated with an increased risk (HR=1.17, 95% CI 1.03 to 1.33, p=0.013) of major relapses. Low-dose GCs were not associated with a reduced major relapse risk (HR=0.96, 95% CI 0.88 to 1.05, p=0.36) but they were associated with a risk of damage accumulation (HR=1.52, 95% CI 1.19 to 1.93, p=0.0007) and hospitalisations (HR=1.24, 95% CI 1.06 to 1.45, p=0.006). CONCLUSION: Higher GC exposure during maintenance therapy was not significantly associated with a lower major relapse risk whereas it was associated with damage accrual and hospitalisation. These findings may support decision making regarding long-term GC use in patients with GPA/MPA.
引用
- Chavatza K, Gialouri CG, Drougkas K, et al. No benefit of adding glucocorticoids to maintenance treatment in reducing the risk of major relapses in ANCA-associated vasculitis: real life data from a longitudinal cohort study. RMD Open. 2026. PMID: 42342286. doi:10.1136/rmdopen-2026-006935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。